----item----
version: 1
id: {3B9C7C64-BBDC-4E70-B569-798D58051626}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/13/CRISPR Therapeutics Appoints Chief Business Officer
parent: {B23F589E-74E7-4CA3-9A57-5AB55E4AFD4B}
name: CRISPR Therapeutics Appoints Chief Business Officer
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: e9056f6f-c2bf-45ae-8e59-1546fcb9319f

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 51

CRISPR Therapeutics Appoints Chief Business Officer
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 51

CRISPR Therapeutics Appoints Chief Business Officer
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1063

<p>CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, has appointed Dr. Samarth Kulkarni chief business officer and Dr. Michael Bruce senior vice-president of program portfolio and alliance management.</p><p>Kulkarni joins CRISPR from McKinsey and Company where he was a partner and had a leading role in the pharmaceutical and medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations.Â </p><p>Bruce joins the firm from Pfizer where he held positions of increasing responsibility over the last five years in the program, portfolio and alliance management functions. Most recently, he held the position of vice-president of development management and business operations for worldwide R&D where he was responsible for the program management of all early stage (preclinical to Phase II) development programs in multiple therapeutic areas and modalities.</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 301

<p>CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, has appointed Dr. Samarth Kulkarni chief business officer and Dr. Michael Bruce senior vice-president of program portfolio and alliance management.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 51

CRISPR Therapeutics Appoints Chief Business Officer
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150813T130001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150813T130001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150813T130001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029496
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 51

CRISPR Therapeutics Appoints Chief Business Officer
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359849
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042434Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

e9056f6f-c2bf-45ae-8e59-1546fcb9319f
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042435Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
